Synlett 2013; 24(20): 2751-2757
DOI: 10.1055/s-0033-1339927
letter
© Georg Thieme Verlag Stuttgart · New York

Ligand-Free, Copper-Catalyzed Ullmann-Type C–N Coupling: Regioselective Synthesis of Azole-Substituted Imidazo[1,2-a]pyridines

Pinku Kaswan
Department of Chemistry, Birla Institute of Technology and Science, Pilani 333031, India   Fax: +91(1596)244183   Email: anilkumar@pilani.bits-pilani.ac.in
,
Kasiviswanadharaju Pericherla
Department of Chemistry, Birla Institute of Technology and Science, Pilani 333031, India   Fax: +91(1596)244183   Email: anilkumar@pilani.bits-pilani.ac.in
,
Anil Kumar*
Department of Chemistry, Birla Institute of Technology and Science, Pilani 333031, India   Fax: +91(1596)244183   Email: anilkumar@pilani.bits-pilani.ac.in
› Author Affiliations
Further Information

Publication History

Received: 30 July 2013

Accepted after revision: 15 September 2013

Publication Date:
06 November 2013 (online)


Abstract

A simple and highly efficient protocol for the regioselective synthesis of azole-substituted imidazo[1,2-a]pyridines has been developed using a ligand-free, copper-catalyzed Ullmann-type C–N coupling of 2-(2-bromophenyl)imidazo[1,2-a]pyridines with different azoles and in situ generated 1,2,3-triazoles. The reactions proceeded smoothly to furnish azolo-imidazo[1,2-a]pyridines in good to excellent yields (65–96%).

Supporting Information

 
  • References and Notes

    • 1a Ullmann F. Ber. Dtsch. Chem. Ges. 1903; 36: 2382
    • 1b Ullmann F. Ber. Dtsch. Chem. Ges. 1904; 37: 853
    • 2a Beletskaya IP, Cheprakov AV. Coord. Chem. Rev. 2004; 248: 2337
    • 2b Liu Y, Wan J.-P. Org. Biomol. Chem. 2011; 9: 6873
    • 2c Monnier F, Taillefer M. Angew. Chem. Int. Ed. 2009; 48: 6954
    • 3a Klapars A, Buchwald SL. J. Am. Chem. Soc. 2002; 124: 14844
    • 3b Antilla JC, Klapars A, Buchwald SL. J. Am. Chem. Soc. 2002; 124: 11684
  • 5 Enguehard C, Allouchi H, Gueiffier A, Buchwald SL. J. Org. Chem. 2003; 68: 4367
    • 6a Gujadhur RK, Bates CG, Venkataraman D. Org. Lett. 2001; 3: 4315
    • 6b Han C, Shen R, Su S, Porco JA. Org. Lett. 2003; 6: 27
    • 7a Shafir A, Buchwald SL. J. Am. Chem. Soc. 2006; 128: 8742
    • 7b Fagan PJ, Hauptman E, Shapiro R, Casalnuovo A. J. Am. Chem. Soc. 2000; 122: 5043
  • 8 Fisher MH, Lusi A. J. Med. Chem. 1972; 15: 982
  • 9 Gueiffier A, Mavel S, Lhassani M, Elhakmaoui A, Snoeck R, Andrei G, Chavignon O, Teulade J.-C, Witvrouw M, Balzarini J, De Clercq E, Chapat J.-P. J. Med. Chem. 1998; 41: 5108
  • 10 Ulloora S, Shabaraya R, Adhikari AV. Bioorg. Med. Chem. Lett. 2013; 23: 3368
  • 11 Baviskar AT, Madaan C, Preet R, Mohapatra P, Jain V, Agarwal A, Guchhait SK, Kundu CN, Banerjee UC, Bharatam PV. J. Med. Chem. 2011; 54: 5013
  • 12 Kaminski JJ, Bristol JA, Puchalski C, Lovey RG, Elliott AJ, Guzik H, Solomon DM, Conn DJ, Domalski MS. J. Med. Chem. 1985; 28: 876
  • 13 Almirante L, Polo L, Mugnaini A, Provinciali E, Rugarli P, Biancotti A, Gamba A, Murmann W. J. Med. Chem. 1965; 8: 305
  • 14 Ismail MA, Brun R, Wenzler T, Tanious FA, Wilson WD, Boykin DW. J. Med. Chem. 2004; 47: 3658
  • 15 Chaouni-Benabdallah A, Galtier C, Allouchi H, Kherbeche A, Debouzy J.-C, Teulade J.-C, Chavignon O, Witvrouw M, Pannecouque C, Balzarini J, De Clercq E, Enguehard C, Gueiffier A. Arch. Pharm. 2001; 334: 224
    • 16a Pericherla K, Khungar B, Kumar A. Tetrahedron Lett. 2012; 53: 1253
    • 16b Pericherla K, Khedar P, Khungar B, Kumar A. Chem. Commun. 2013; 49: 2924
    • 16c Khedar P, Pericherla K, Kumar A. Synlett 2012; 23: 2609
  • 17 Sun M, Wu H, Zheng J, Bao W. Adv. Synth. Catal. 2012; 354: 835
  • 18 Sperotto E, van Klink GP. M, van Koten G, de Vries JG. Dalton Trans. 2010; 39: 10338
    • 19a Hu Y.-Y, Hu J, Wang X.-C, Guo L.-N, Shu X.-Z, Niu Y.-N, Liang Y.-M. Tetrahedron 2010; 66: 80
    • 19b Eglinton G, Galbraith AR. J. Chem. Soc. 1959; 889
  • 20 General Procedure for the Synthesis of Compound 3 A round-bottom flask (10 mL) was charged with 2-(2-bromophenyl)imidazo[1,2-a]pyridine (1, 0.36 mmol), azole 2 (0.439 mmol), CuI (0.07 mmol), K2CO3 (0.732 mmol), and DMF (2.0 mL). The resulting solution was stirred at 150 °C in an oil bath for 2 h under nitrogen atmosphere. On completion, the reaction mass was filtered through Celite and washed with EtOAc. The filtrate was washed with H2O, dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The crude residue was purified by column chromatography (EtOAc–hexane, 2:3) to obtain the product 3.
  • 21 General Procedure for the Synthesis of Compound 6 A round-bottom flask (10 mL) was charged with 2-(2-bromophenyl)imidazo[1,2-a]pyridine (1, 0.36 mmol), sodium azide (4, 0.439 mmol), phenylacetylene (5a, 0.439 mmol), CuCl2·2H2O (0.073 mmol), K2CO3 (0.732 mmol), and DMF (2.0 mL). The resulting solution was stirred at 100 °C in an oil bath for 3 h. On completion, the reaction mass was filtered through Celite and washed with EtOAc. The filtrate was washed with H2O, dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The crude residue was purified by column chromatography (EtOAc–hexane, 2:3) to obtain product 6.
  • 22 Spectroscopic Data of Selected Compounds 2-[2-(1H-Imidazol-1-yl)phenyl]H-imidazo[1,2-a]pyridine (3a) Yield 92%; colorless solid; mp 149–151 °C. 1H NMR (400 MHz, CDCl3): δ = 8.42 (dd, J = 7.9, 1.4 Hz, 1 H), 7.89 (dt, J = 6.8, 1.1 Hz, 1 H), 7.65–7.55 (m, 3 H), 7.44 (td, J = 7.6, 1.5 Hz, 1 H), 7.34 (dd, J = 7.8, 1.2 Hz, 1 H), 7.29 (s, 1 H), 7.18–7.14 (m, 1 H), 7.06 (s, 1 H), 6.73 (td, J = 6.8, 1.1 Hz, 1 H), 6.29 (s, 1 H). 13C NMR (126 MHz, CDCl3): δ = 144.86, 140.10, 137.36, 134.31, 131.38, 129.95, 129.78, 129.67, 128.37, 127.71, 125.82, 125.06, 120.48, 117.43, 112.53, 109.70. HRMS: m/z calcd for C16H13N4 +: 261.1135; found: 261.1119 [M + H]+. 2-[2-(4-Methyl-1H-imidazol-1-yl)phenyl]H-imidazo [1,2-a]pyridine (3b) Yield 90%; colorless; mp 174–177 °C. 1H NMR (300 MHz, CDCl3): δ = 8.41 (dd, J = 7.9, 1.4 Hz, 1 H), 7.90 (dt, J = 6.8, 1.0 Hz, 1 H), 7.62–7.52 (m, 2 H), 7.47 (s, 1 H), 7.40 (td, J = 7.6, 1.5 Hz, 1 H), 7.32–7.26 (m, 1 H), 7.18–7.11 (m, 1 H), 6.76 (s, 1 H), 6.72 (td, J = 6.8, 1.1 Hz, 1 H), 6.40 (s, 1 H), 2.34 (s, 3 H). 13C NMR (75 MHz, CDCl3): δ = 144.82, 140.26, 138.83, 136.50, 134.55, 131.26, 129.88, 129.43, 128.30, 127.79, 125.84, 124.96, 117.43, 116.77, 112.46, 109.88, 13.76. HRMS: m/z calcd for C17H15N4 +: 275.1291; found: 275.1278 [M + H]+. 2-[2-(4-Phenyl-1H-1,2,3-triazol-1-yl)phenyl]H-imidazo[1,2-a]pyridine (6a) Yield 76%; off-white solid; mp 189–192 °C. 1H NMR (300 MHz, DMSO-d 6): δ = 8.89 (s, 1 H), 8.43 (d, J = 6.8 Hz, 1 H), 8.29 (d, J = 7.8 Hz, 1 H), 7.93 (d, J = 7.3 Hz, 2 H), 7.79–7.69 (m, 1 H), 7.59 (d, J = 3.1 Hz, 2 H), 7.51 (d, J = 4.8 Hz, 1 H), 7.46 (d, J = 7.7 Hz, 2 H), 7.36 (t, J = 7.3 Hz, 1 H), 7.27–7.15 (m, 1 H), 6.93 (s, 1 H), 6.80 (t, J = 6.7 Hz, 1 H). 13C NMR (75 MHz, DMSO-d 6): δ = 147.98, 145.06, 140.34, 134.62, 131.26, 130.65, 130.56, 130.40, 128.86, 128.44, 128.29, 127.47, 126.15, 125.84, 125.00, 122.05, 117.55, 112.53, 110.39. HRMS: m/z calcd for C21H16N5 +: 338.1400; found: 338.1405 [M + H]+.